Clinical trials located in

Corbeil-Essonnes

Corbeil-Essonnes city is located in France. Currently, 5 clinical trials are being conducted in this city.

Corbeil-Essonnes, located in the Île-de-France region of France, is a city rich in history and culture. It emerged from the merger of two towns, Corbeil and Essonnes, in 1951. The city is known for its historical mills, which played a significant role in its economic development, especially during the Middle Ages. The Seine River, which flows through Corbeil-Essonnes, has been pivotal in shaping the city’s landscape and facilitating trade. Notably, the Cathedral Saint-Spire, with its stunning architecture, stands as a testament to the city’s medieval past. Corbeil-Essonnes also boasts a vibrant arts scene, hosting various cultural events and festivals throughout the year.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Assessing new drug impact on chronic diabetic peripheral neuropathic pain

    This study focuses on testing a new medicine called GSK3858279 for people living with chronic Diabetic Peripheral Neuropathic Pain that’s not been well-managed. The medicine will be given to some people selected at random, while others will receive a placebo. It’s important that neither the patient nor the doctors will know who received the drug and who got the placebo. The main aim is to check how well GSK3858279 works for nerve pain. Participants will keep track of their pain daily using a simple scale from 0 (no pain) to 10 (worst imaginable pain). These daily scores will then be added up each week. Additionally, any health issues occurring during the study will be closely monitored, regardless of their relation to GSK3858279.

    • GSK3858279- new potential medication for chronic pain associated with osteoarthritis
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in France:

.